ESMO open · 2025
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pesántez D, Brasó-Maristany F, Pascual T, Angelats L, Indacochea A, Cuatrecasas M, López S, Sanfeliu E, Fernández-Esparrach G, Notario L, Méndez I, Momblan D, Candia L, Macias I, Prat A, Sauri T
Аннотация
BACKGROUND: Response to trastuzumab combined with chemotherapy (T-chemo) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) varies widely, highlighting the need for more precise biomarkers beyond conventional HER2 assessment with immunohistochemistry (IHC) and in situ hybridization (ISH). The HER2DX ERBB2 messenger RNA (mRNA) assay, a clinically validated genomic test initially developed for early-stage HER2-positive breast cancer, quantitatively measures ERBB2 expression and may improve patient selection for T-chemo in AGC.
PATIENTS AND METHODS: In a retrospective cohort of 134 patients with AGC, including 58 who received T-chemo, we evaluated whether the HER2DX ERBB2 score defines more accurately HER2 status and correlates with treatment response and survival outcomes in HER2-positive AGC, compared with standard pathology-based methods.
RESULTS: Our findings demonstrate that a high HER2DX ERBB2 score was significantly associated with improved progression-free survival [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69-0.95, P = 0.012] and overall survival (HR 0.43, 95% CI 0.23-0.81, P = 0.008).
CONCLUSIONS: These results suggest that ERBB2 mRNA expression, as measured by HER2DX, may help refine selection for T-chemo and guide more personalized treatment strategies in HER2-positive AGC.
PATIENTS AND METHODS: In a retrospective cohort of 134 patients with AGC, including 58 who received T-chemo, we evaluated whether the HER2DX ERBB2 score defines more accurately HER2 status and correlates with treatment response and survival outcomes in HER2-positive AGC, compared with standard pathology-based methods.
RESULTS: Our findings demonstrate that a high HER2DX ERBB2 score was significantly associated with improved progression-free survival [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69-0.95, P = 0.012] and overall survival (HR 0.43, 95% CI 0.23-0.81, P = 0.008).
CONCLUSIONS: These results suggest that ERBB2 mRNA expression, as measured by HER2DX, may help refine selection for T-chemo and guide more personalized treatment strategies in HER2-positive AGC.